Estriol

CAS No. 50-27-1

Estriol( E3 | 16α-hydroxy-17β-estradiol | 1,3,5(10)-Estratriene-3,16α,17β-triol )

Catalog No. M14701 CAS No. 50-27-1

Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast Y cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
50MG 33 In Stock
100MG 50 In Stock
500MG 65 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Estriol
  • Note
    Research use only, not for human use.
  • Brief Description
    Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast Y cells.
  • Description
    Estriol is an antagonist of the G-protein coupled estrogen receptor in estrogen receptor-negative breast Y cells.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    E3 | 16α-hydroxy-17β-estradiol | 1,3,5(10)-Estratriene-3,16α,17β-triol
  • Pathway
    Endocrinology/Hormones
  • Target
    Estrogen Receptor/ERR
  • Recptor
    ER| MRP1
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    50-27-1
  • Formula Weight
    288.39
  • Molecular Formula
    C18H24O3
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 10 mg/mL (34.67 mM); DMSO: 57 mg/mL (197.64 mM)
  • SMILES
    OC1=CC=C2[C@@]3([H])CC[C@]4(C)[C@@H](O)[C@H](O)C[C@@]4([H])[C@]3([H])CCC2=C1
  • Chemical Name
    (8R,9S,13S,14S,16R,17R)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,16,17-triol

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Lappano R, et al. Mol Cell Endocrinol. 2010, 320(1-2), 162-170.
molnova catalog
related products
  • Clomiphene citrate

    A non-steroidal, a widely used fertility agent that inhibits estrogen receptor in the hypothalamus.

  • Lasofoxifene Tartrat...

    Lasofoxifene Tartrate?is a third-generation non-steroidal selective estrogen receptor modulator.

  • Medicarpin (b)

    (+)-Medicarpin potently inhibits osteoclastogenesis and promotes bone healing and increases bone mass by osteoblast differentiation with estrogen receptor (ER) β-mediated osteogenic action.